Day: June 7, 2023
DENVER, June 07, 2023 (GLOBE NEWSWIRE) — Atlas Technical Consultants Inc. (Atlas), a leading infrastructure and environmental solutions provider, has expanded its footprint with the opening of a new hub office in Denver, Colorado. The new hub will serve as the growth and service provider for the Mountain Region.
“Denver’s long-range plan for the region includes complete neighborhoods and complete transportation networks; a measured, common-sense approach to new growth; and land-use decisions through the lens of social equity,” Atlas Chief Operating Officer Ken Burns said. “This aligns with Atlas overarching goals to build sustainable and resilient communities and to offer bold, smart, innovative solutions and by staying flexible and close to our clients in economically vibrant regions like the Rocky Mountain area.”
All four of...
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Written by Customer Service on . Posted in Public Companies.
WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. PT.
The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.
About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in...
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
Written by Customer Service on . Posted in Public Companies.
Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023
INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that it will host a virtual Investor Day on Tuesday, June 20, 2023, at 12:00 PM ET. The webcast is expected to last approximately 90 minutes.
The event will include presentations by the Executive team on:POINT’s vertically integrated and highly differentiated platform for the development and commercialization of radiopharmaceuticals, highlighting the Company’s foundational investments into supply chain and manufacturing
The significance and breadth of the untapped potential for radioligand therapy today and the...
Angus Gold Intersects More High-Grade Intervals of up to 5.1 g/t Au Over 8.0 Metres at the Dorset Gold Zone, Golden Sky Project
Written by Customer Service on . Posted in Public Companies.
Figure 1
Surface Map – Dorset Gold Trend new drilling, Golden Sky Project Location MapHighlights:Winter 2023 infill drilling program at the Dorset Zone intersected significant gold mineralization including 5.1 g/t Au over 8.0 metres within a broader zone of 2.8 g/t Au over 16.0 metres and 3.4 g/t Au over 6.0 metres within a wider interval of 2.2 g/t Au over 16.0 metres
Nine (9) of the final fifteen (15) winter drill holes were completed as infill holes on the Dorset Zone resource area and all holes intersected gold mineralization
The 2023 Summer drilling program focused on the Banded Iron Formation is scheduled to begin on June 8th and will test new exploration targets generated by the extensive ground geophysics programs completed earlier this yearTORONTO, June 07, 2023 (GLOBE NEWSWIRE) — Angus Gold Inc. (TSX-V: GUS | OTC:...
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress
Written by Customer Service on . Posted in Public Companies.
Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital
TNX-1500 is Expected to Enter Phase 1 Clinical Development in Third Quarter 2023
CHATHAM, N.J, June 07, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from two oral presentations and one poster presentation at the 2023 American Transplant Congress (ATC) by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital. The data involve studies of Tonix’s TNX-1500 (Fc-modified anti-CD40L monoclonal antibody) in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Copies of the presentations are available...
Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California
Written by Customer Service on . Posted in Public Companies.
GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and University of California, Davis (UC Davis), today announce an agreement to roll out proprietary Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) at medical or academic institutions within the University of California system. The partnership agreement sets out a staged approach through which Orgenesis will install and operate OMPULs™, enabling their proprietary point-of-care (“POCare”) Service Platform to manufacture therapeutics at hospitals throughout California, empowering onsite production for clinical trials like the cell and gene therapies in development...
Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
Written by Customer Service on . Posted in Public Companies.
Topline results from the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis are expected in Q4 2023
ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 SERENITY trial of VTX958 in plaque psoriasis.
“I am very proud of our team’s execution as we mark another important milestone for Ventyx and for ulcerative colitis and plaque psoriasis patients,” said Dr. William Sandborn, President and Chief Medical...
Plug Supplies 8 MW of Hydrogen Fuel Cells to Energy Vault to Displace Diesel Generators in California Wine Country
Written by Customer Service on . Posted in Public Companies.
Plug Fuel Cells Will Displace Diesel Generators to Power Microgrid During Wildfires and Other Emergencies in California Wine Country
LATHAM, N.Y., June 07, 2023 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a leading provider of turnkey hydrogen solutions for the global green hydrogen economy, announced it will supply Energy Vault Holdings, Inc. with 8 MW (megawatts) of hydrogen fuel cell stationary power to deliver clean energy to the city of Calistoga, located in California Wine Country, during times of wildfires and other emergencies. This will be the largest planned hydrogen powered fuel cell installation in the United States.
The California Public Utility Commission (CPUC) requires that state utility grid operators shut off power during severe weather to help prevent wildfires. Energy Vault has typically rented mobile...
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
Written by Customer Service on . Posted in Public Companies.
Study did not meet the primary endpoint
Pamrevlumab was generally safe and well tolerated
Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. The study did not meet the primary endpoint of Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52 compared to baseline. Pamrevlumab was generally safe and well tolerated and the majority of treatment emergent adverse events were mild or moderate.
FibroGen plans to present the complete results of the LELANTOS-1 study at an upcoming medical...
Reliance Steel & Aluminum Co. Announces Participation at the 2023 Wells Fargo Industrials Conference
Written by Customer Service on . Posted in Public Companies.
SCOTTSDALE, Ariz., June 07, 2023 (GLOBE NEWSWIRE) — Reliance Steel & Aluminum Co. (NYSE: RS) announced today that Karla Lewis, Chief Executive Officer, and Steve Koch, Chief Operating Officer, will participate in the 2023 Wells Fargo Industrials Conference on Wednesday, June 14th at the InterContinental Chicago Magnificent Mile. Reliance is scheduled to present at 11:45 a.m. CT and will participate in meetings with investors throughout the day.
The presentation will be webcast live over the Internet, hosted on the Investors section of the Company’s website at investor.rsac.com. In addition to the live webcast, a replay will be available on the Company’s website for 90 days following the event.
About Reliance Steel & Aluminum Co. Founded in 1939, Reliance Steel & Aluminum Co. (NYSE: RS) is a leading global...